The Chassys platform has been successfully applied for the identification of a series of putative pharmacological chaperones for the treatment of congenital erythropoietic porphyria. One of them is currently being validated, with most promising results.

See also “Una molécula ‘carabina’ para aplacar la porfiria congénita”.